IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
…
28,250$
-1,70%
Echtzeit-Aktienkurs IDEAYA Biosciences
Bid:
Ask:
Nachrichten zur IDEAYA Biosciences Aktie
IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
…
IDEAYA Biosciences, Inc. (IDYA) Presents at Citis 2025 SMID Cap Biopharma Call Series Transcript
…
Ideaya Biosciences: JPMorgan sieht 186 % Kurspotenzial und setzt den Biotech auf die "Positive Catalyst Watch"
Ideaya Biosciences (IDYA) positioniert sich als ein auf Präzisionsonkologie spezialisiertes Biotechnologieunternehmen mit einem klaren Fokus auf die Entwicklung zielgerichteter Krebstherapien.…
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849
…
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later
…
Down -8.63% in 4 Weeks, Heres Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
The heavy selling pressure might have exhausted for IDEAYA Biosciences (IDYA) as it is technically in oversold territory now. In…
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -122.39% and 0%, respectively, for the quarter ended December 2024. Do…
Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming
…
Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash
…
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.…
Stocks making the biggest moves midday: Paramount Global, Morphic Holding, Ideaya Biosciences and more
These are the stocks posting the largest moves in midday trading.…
Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?
…